Cancer Often Leads to Stopping MS Medicines

Credibility

Interest

Key Takeaway

After being diagnosed with cancer, people with MS were much less likely to keep taking disease-modifying drugs, but their visits to neurologists and hospital stays for MS did not change much.

What They Found

Researchers looked at health records for people with MS in France and British Columbia around the time some were diagnosed with cancer. They compared each person with cancer to two similar people with MS who did not get cancer, checking two years before and two years after the cancer diagnosis. The biggest change was a sharp drop in use of disease-modifying therapies (DMTs) after a cancer diagnosis, especially for people also receiving chemotherapy. Visits to neurologists stayed about the same before and after cancer, meaning people still saw their MS doctors at similar rates. Hospital stays for MS also did not show a large change after cancer compared with people without cancer.

Who Should Care and Why

People with MS and their caregivers should know that a new cancer diagnosis often leads to stopping or reducing MS drugs, which can affect long-term MS control. This matters because DMTs help lower MS relapses and slower disability; stopping them is like taking away a tool you use to manage the condition. Oncologists and neurologists should coordinate care — like teammates passing a ball — so cancer treatment and MS management stay balanced and safe. Caregivers may need to help track medication changes and watch for MS symptoms if DMTs are stopped. Health systems and clinics might use these findings to ensure people with both MS and cancer get clear plans about who manages which treatments and how follow-up will happen.

Important Considerations

This study used large health records but could not tell why doctors or patients stopped DMTs — reasons could include cancer type, drug interactions, or safety concerns. The study shows patterns (what happened) but cannot prove that stopping DMTs causes any specific MS outcomes (it is not a controlled experiment). Also, the results come from two regions and may not apply exactly the same way in other countries, hospitals, or for every type of cancer.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Diagnostics Caregivers

Article Topics:

Multiple sclerosiscancerdisease-modifying therapiesepidemiologyhealthcare use

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News